Colorectal Cancer — Research Intelligence Dashboard
Prototype dashboard for architecture validation. Metrics shown are illustrative until registry enrichment and GRMI calculation engine are live.
Executive Summary
Data snapshot: February 2026
520
Total Active Trials
ClinicalTrials.gov Registry Subset
176
New Trials
Rolling 12 Months
23.8%
Phase I Density
Percentage
28
Distinct Biomarkers
Active
Accelerating
Research Momentum Classification (Rolling 12-Month Model)
Global Research Momentum Index (GRMI)
88
GRMI ScoreComposite index weighted as:
• Trial Velocity (30%)
• Early-Phase Density (25%)
• Biomarker Diversity (20%)
• Modality Expansion (15%)
• Geographic Spread (10%)
• Trial Velocity (30%)
• Early-Phase Density (25%)
• Biomarker Diversity (20%)
• Modality Expansion (15%)
• Geographic Spread (10%)
Accelerating
12-Month Trend
Component Breakdown
91
Trial Velocity Score
87
Early Phase Density
84
Biomarker Diversity
89
Modality Expansion
86
Geographic Spread
Phase & Modality Distribution
Phase Distribution
Modality Distribution
Geographic Spread
43
Countries Active
267
United States
Active Trials
167
Europe
Active Trials
86
Asia-Pacific
Active Trials
12-Month Geographic Expansion:+8 new countries, +71 new trial sites
Centers Actively Studying This Area
Institutions listed based on active colorectal cancer trial count ≥ 30 (ClinicalTrials.gov registry analysis).
| Institution Name | Active Trials | Phase I % | Dominant Modality | Distinct Biomarkers |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 49 | 31% | Immunotherapy | 19 |
| MD Anderson Cancer Center | 56 | 36% | Combination | 22 |
| Dana-Farber Cancer Institute | 42 | 28% | Targeted Therapy | 17 |
| Johns Hopkins Hospital | 38 | 34% | Immunotherapy | 16 |
| Mayo Clinic | 34 | 26% | Combination | 14 |
| University of California, San Francisco | 36 | 39% | KRAS-targeted | 18 |
Institutional Research Footprint Overlay
Institutional Overlay (Phase II Modeling)
This section will display global baseline vs. selected institution metrics side-by-side, enabling comparative analysis of institutional research positioning.
What This Signals
MSI-high immunotherapy subset expanding
MSI-high/dMMR-targeted immunotherapy trials increased 76%, reflecting PD-1/PD-L1 validation
KRAS-targeted activity accelerating
KRAS G12C-targeted trials increased following sotorasib/adagrasib approvals in other indications
Biomarker stratification increasing
28 distinct biomarkers active, including BRAF V600E, HER2, NRAS mutations beyond traditional markers
Bispecific and ADC modalities emerging
Bispecific antibodies and ADC trials increased 68% combined, reflecting novel modality expansion
